Top

Cardiovascular Drugs and Therapy

Published in:

Open Access 01-08-2008 | Editorial

ACE-inhibitors, Beta-blockers or the Combination in Heart Failure: Is It Just an A–B–C ?

EDITORIAL to: Effects of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure by Rosenberg et al.

Authors: Rudolf A. de Boer, Dirk J. van Veldhuisen

Published in: Cardiovascular Drugs and Therapy | Issue 4/2008

Excerpt

During the last decades, the pharmacotherapy of heart failure (HF) has changed dramatically. Large-scale trials have been conducted that have indisputably shown the efficacy of angiotensin-converting enzyme inhibitors (ACE-I) and beta-adrenergic receptor blockers (β-blockers). These and other therapies have improved the overall outcome of patients with HF, although prognosis remains bleak. …

Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007;50:2357–68.PubMedCrossRef

Tjeerdsma G, de Boer RA, Boomsma F, van den Berg MP, Pinto YM, van Veldhuisen DJ. Rapid bedside measurement of brain natriuretic peptide in patients with chronic heart failure. Int J Cardiol 2002;86:143–9.PubMedCrossRef

de Boer RA, Henning RH, Suurmeijer AJ, Pinto YM, Olthof E, Kirkels JH, van Gilst WH, Crijns HJ, van Veldhuisen DJ. Early expression of natriuretic peptides and SERCA in mild heart failure: association with severity of the disease. Int J Cardiol 2001;78:5–12.PubMedCrossRef

Suo M, Hautala N, Földes G, Szokodi I, Tóth M, Leskinen H, Uusimaa P, Vuolteenaho O, Nemer M, Ruskoaho H. Posttranscriptional control of BNP gene expression in angiotensin II-induced hypertension. Hypertension 2002;39:803–8.PubMedCrossRef

Majalahti T, Suo-Palosaari M, Sármán B, Hautala N, Pikkarainen S, Tokola H, Vuolteenaho O, Wang J, Paradis P, Nemer M, Ruskoaho H. Cardiac BNP gene activation by angiotensin II in vivo. Mol Cell Endocrinol 2007;273:59–67.PubMedCrossRef

Bhalla SS, Robitaille L, Nemer M. Cooperative activation by GATA-4 and YY1 of the cardiac B-type natriuretic peptide promoter. J Biol Chem 2001;276:11439–45.PubMedCrossRef

Marttila M, Hautala N, Paradis P, Toth M, Vuolteenaho O, Nemer M, Ruskoaho H. GATA4 mediates activation of the B-type natriuretic peptide gene expression in response to hemodynamic stress. Endocrinology 2001;142:4693–700.PubMedCrossRef

White M, Lepage S, Lavoie J, De Denus S, Leblanc MH, Gossard D, Whittom L, Racine N, Ducharme A, Dabouz F, Rouleau JL, Touyz R. Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure. J Card Fail 2007;13:86–94.PubMedCrossRef

He Q, Mendez M, LaPointe MC. Regulation of the human brain natriuretic peptide gene by GATA-4. Am J Physiol Endocrinol Metab 2002;283:E50–7.PubMed

10.

Davis ME, Richards AM, Nicholls MG, Yandle TG, Frampton CM, Troughton RW. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 2006;113:977–85.PubMedCrossRef

11.

Sanderson JE, Chan WW, Hung YT, Chan SK, Shum IO, Raymond K, Woo KS. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J 1995;74:502–7.PubMedCrossRef

12.

Rosenberg J, Gustafsson F, Remme WJ, Riegger GAJ, Hildebrandt PR. The prognostic value of B-type natriuretic peptides during beta-blocker therapy in stable patients with systolic heart failure. Cardiovasc Drugs Ther 2008 (this issue).

13.

van Veldhuisen DJ, Genth-Zotz S, Brouwer J, Boomsma F, Netzer T, Man In’T Veld AJ, Pinto YM, Lie KI, Crijns HJ. High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 1998;32:1811–8.PubMedCrossRef

14.

Remme WJ. Should ACE inhibition always be first-line therapy in heart failure? Lessons from the CARMEN Study. Cardiovasc Drugs Ther 2003;17:107–9.PubMedCrossRef

15.

de Boer RA, van Veldhuisen DJ. Polypharmacy in chronic heart failure: practical issues regarding the use of angiotensin-converting enzyme inhibitors, beta-blockers and other drugs. Eur Heart J Suppl 2002;4(D):D111–6.

16.

Komajda M, Lapuerta P, Hermans N, Gonzalez-Juanatey JR, van Veldhuisen DJ, Erdmann E, Tavazzi L, Poole-Wilson P, Le Pen C. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 2005;26:1653–9.PubMedCrossRef

17.

Remme WJ, Riegger G, Hildebrandt P, Komajda M, Jaarsma W, Bobbio M, Soler-Soler J, Scherhag A, Lutiger B, Rydén L. The benefits of early combination treatment of carvedilol and an ACE-inhibitor in mild heart failure and left ventricular systolic dysfunction. The carvedilol and ACE-inhibitor remodelling mild heart failure evaluation trial (CARMEN). Cardiovasc Drugs Ther 2004;18:57–66.PubMedCrossRef

18.

Sliwa K, Norton GR, Kone N, Candy G, Kachope J, Woodiwiss AJ, Libhaber C, Sareli P, Essop R. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure. J Am Coll Cardiol 2004;44:1825–30.PubMedCrossRef

19.

Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, Ponikowski P, Skene A, van de Ven L, Verkenne P, Lechat P, CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005;112:2426–35.PubMedCrossRef

Title: ACE-inhibitors, Beta-blockers or the Combination in Heart Failure: Is It Just an A–B–C ?
EDITORIAL to: Effects of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure by Rosenberg et al.
Authors: Rudolf A. de Boer
Dirk J. van Veldhuisen
Publication date: 01-08-2008
Publisher: Springer US
Published in: Cardiovascular Drugs and Therapy / Issue 4/2008
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-008-6107-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

ACE-inhibitors, Beta-blockers or the Combination in Heart Failure: Is It Just an A–B–C ?

EDITORIAL to: Effects of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure by Rosenberg et al.

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2008

Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit

Effects of Folic Acid on Cardiac Myocyte Apoptosis in Rats with Streptozotocin-induced Diabetes Mellitus

Erythropoietin Stimulates Normal Endothelial Progenitor Cell-Mediated Endothelial Turnover, but Attributes to Neovascularization Only in the Presence of Local Ischemia

Antiapoptosis and Mitochondrial Effect of Pioglitazone Preconditioning in the Ischemic/reperfused Heart of Rat

Administration of the Rho-Kinase Inhibitor Fasudil Before Ischemia or just After Reperfusion, but not 30 min After Reperfusion, Protects the Stunned Myocardium in Swine

Effect of Beta-blockade and ACE Inhibition on B-type Natriuretic Peptides in Stable Patients with Systolic Heart Failure